ClinicalTrials.gg
RecruitingNCT02889003PIO2STOPUpdated Jul 6, 2026

Second STOP After Pioglitazone Priming in CML Patients

A Phase 2 interventional study of Pioglitazone + TKI in Chronic Myeloid Leukemia (CML), sponsored by Versailles Hospital. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Versailles Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2016; still recruiting 9 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France — 15 open to participants now, 24 under way, 4 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France.

Planned enrollment
75th of 83
26 · median 150
Started
2016
with 4 others
Phase 2
33 of 103
3 open now
Primary completion
2027-12
later than 11 of 23 live
Registered
67th of 103
by date
Lead sponsor
3 of 103
Versailles Hospital

Among the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France, this one is the 75th largest by planned enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2016, is one of 33 in phase 2, reaches primary completion later than 11 of the 23 other live ones, and was the 67th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

15 of the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France, or all of them as a file.
02

Study summary

Single-center study, prospective, phase II trial.

The study objectives are :

  • To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI discontinuation.
  • To assess survival without loss of MMR over a 12 months period following a second TKI discontinuation in subjects who achieve or maintain \< MR4.5 with the combination PIO and TKI administered for at least 6 months.
03

Conditions studied

  • Chronic Myeloid Leukemia (CML)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CML in any phase. patient in MR4
  2. Loss of MMR following a first or subsequent TKI discontinuation trial.
  3. Patient prior treated with imatinib, dasatinib, nilotinib, or bosutinib
  4. Age >18 years.
  5. Serum \<1.5 x values.
  6. (SGOT)/ALT (SGPT) \<2.5x upper limit of normal values.
  7. Females of child bearing potential must agree to abstain from sexual activity or to use a medically approved measure/regimen during and for 3 months after the treatment period. Women of child bearing potential must have a negative urine pregnancy test at the time of enrollment. Acceptable methods of birth control include oral contraceptive, intrauterine device, transdermal/implanted or injected contraceptives and abstinence.
  8. Males must agree to abstain from sexual activity or agree to utilize a medically-approved contraception method during and for 3 months after the treatment period.
  9. Signed .
  10. Be able and willing to comply with study visits and procedures

Exclusion criteria

Exclusion Criteria:

  1. Known loss of CCyR by marrow cytogenetic or blood FISH for BCR-ABL1.
  2. Loss of CHR.
  3. Participation in another clinical trial with any investigative drug within 30 days prior to study enrolment.
  4. Prior hematopoietic stem cell transplantation.
  5. Patient requiring anti-diabetic medications to manage hyperglycemia.
  6. Cardiovascular disease: history of congestive heart failure, myocardial infarction within the 6 months of study entry, symptomatic cardiac arrhythmia requiring treatment.
  7. Hepatic insufficiency
  8. History of bladder cancer.
  9. Diagnosed hematuria.
  10. Known osteoporosis with curative therapy (prophylactic therapy is not an exclusion criteria)
  11. Known history of macular edema.
  12. Known history of ABL1-domain mutation associated with resistance to the discontinued TKI.
  13. Known allergy to PIO.
  14. Pregnant or breastfeeding.
  15. Use of TZD within 28 days prior to enrollment.
  16. Significant gastrointestinal condition that could potentially impair the absorption or disposition of the drug.
  17. Uncontrolled peripheral edema (2+ or more) of any etiology
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    CML patients following molecular response loss

    Drug: Pioglitazone + TKI

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: Up to 24 months after inclusion

  2. Treatment free survival after pioglitazone and tyrosine kinase inhibitor discontinuation.

    Time frame: Up to 24 months after inclusion

07

Study locations

3 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2016 (actual). Primary completion is estimated for Dec 2027, 132 months after the start.

Of 99 non-industry phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 130. This study's planned 132 months is above that.

Counting every sponsor, half of 124 studies reached it within 73 months; a quarter within 42 and three quarters within 121.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2016
First posted
Sep 5, 2016
StartActual
Dec 2016
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02889003
Lead sponsor
Versailles Hospital
Responsible party
Philippe ROUSSELOT (Investigator coordinator, Versailles Hospital) — Principal investigator
First posted
Sep 5, 2016
Start date
Dec 2016
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 6, 2026

Study contacts

Sandrine Roux, MC
Contact
sroux@ght78sud.fr
+33139239777

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion